Diarrhea and constipation are also commonly observed, each potentially affecting ten to fifteen percent of patients, with individual susceptibility varying based on factors such as baseline gastrointestinal function, dietary habits, and concurrent medications
It was introduced to the market by Zhejiang Peptites Biotech Co., Ltd on October 26, 2022
This is a frequent inquiry among patients exploring semaglutide weight loss
Frequently Asked Questions Q
Given the increasing emphasis on the use of GLP-1 RAs in clinical practice, it is important that all members of the healthcare team, including pharmacy professionals, understand current recommendations and patient-specific considerations for use
For individuals using GLP-1 for weight management, learning about dietary and lifestyle options may complement their medication regimen